Providing Enabling Disclosure for AI inventions at the EPO

Published September 2025

Providing Enabling Disclosure for AI inventions at the EPO

Video overview:

The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications to be challenged at the EPO. This is important to bear in mind when first drafting a patent application, because it cannot be resolved by later amendment or addition to the application.

The core invention of AI-related patent application often lies in the practical implementation to solve a real-world problem. It’s therefore not uncommon for AI inventions to be claimed as a “black box” and this can cause problems at the EPO. There is a growing body of appeal cases at the EPO Boards of Appeal which have ended with refusal of an AI-related patent application for sufficiency.

The EPO Guidelines have been updated and appear to be more lenient than the body of appeal cases suggests. Our advice based on this is to describe at least one embodiment in enough detail which would enable a skilled person to build, train and implement the machine learning aspect of an invention.

 

Latest updates

Event - 12th November 2026

HGF Partners with PPTI for 'Designing Foods for Healthy Aging' Webinar

As healthy aging, metabolic health and weight management rise up the consumer agenda, food and nutrition businesses are increasingly looking beyond traditional product development and towards solutions that deliver measurable …

Event details
Event - 15th December 2026

Basel Seminar: Seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU

Venue – Der Teufelhof Basel, Switzerland We are pleased to invite you to our seminar on the new EU Pharma Package and its implications for regulatory exclusivities in the EU. …

Event details
Event - 28th October 2026

HGF Attending BMCS Antibody–Drug Conjugates 2026

HGF is pleased to announce that Dr Thomas Lonsdale, Patent Director, will be attending the BMCS Antibody–Drug Conjugates 2026 meeting, taking place on 19 November 2026 at GSK, Stevenage, UK. …

Event details

Hsu Min Chung Recognised in IAM Global Leaders 2027

HGF is delighted to announce that Partner, Hsu Min Chung, has been recognised in the IAM Global Leaders 2027 guide, a prestigious ranking that highlights some of the world’s leading …

Read article
Event - 28th October 2026

HGF Attending the KINPA Conference 2026

HGF is pleased to be attending the KINPA Conference 2026, taking place on 28 October in Seoul, South Korea. Recognised as Korea’s largest intellectual property gathering, the conference brings together …

Event details
Event - 17th - 19th November 2026

HGF Attending IPBC Asia 2026

HGF is pleased to announce that Partner, Dr Jennifer Uno, will be attending IPBC Asia 2026, taking place from 17-19 November 2026 in Tokyo, Japan. The event is one of …

Event details

HGF Recognised in the Chambers and Partners UK 2027 Guide

HGF is proud to announce that we have once again been recognised in the Chambers and Partners UK 2027 Guide, with outstanding rankings for both the firm and individual practitioners …

Read article
Event - 4th November 2026

IAM Navigating the UPC conference

HGF are gold sponsors of the IAM Live Navigating the UPC conference. IAM Live: Navigating the UPC returns to Paris in November bringing together over 180 industry leaders for an …

Event details